330792-70-6

Basic information

• Product Name: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile
• Synonyms: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile;3-AMino-4-cyano-5-(4-phenoxyphenyl)pyrazole;1H-Pyrazole-4-carbonitrile, 3-aMino-5-(4-phenoxyphenyl)-;3-amino-5-(4-phenoxyphenyl)-1H-Pyrazole-4-carbonitrile
• CAS NO: 330792-70-6
• Molecular Formula: C₁₆H₁₂N₄O
• Molecular Weight: 276.29268
• Mol File: 330792-70-6.mol

Chemical Properties

• Boiling Point: 585.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.83±0.50(Predicted)
• CAS DataBase Reference: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(330792-70-6)
• EPA Substance Registry System: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(330792-70-6)

Safety Data

• Hazardous Substances Data: 330792-70-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile is used as a reactant for the preparation of ring-fused pyrazole derivatives, which are known to be inhibitors of lymphocyte-specific kinase (Lck). These derivatives have potential applications in the development of drugs targeting autoimmune diseases and other conditions related to the immune system.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile serves as a valuable building block for the creation of more complex molecules with diverse applications. Its reactivity and structural features make it a useful component in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 109-77-3 malononitrile 
• 108-95-2 phenol 
• 619-44-3 methyl 4-iodobenzoate 
• 330792-68-2 2-[hydroxy-(4-phenoxy-phenyl)-methylene]-malononitrile 
• 1623-95-6 4-phenoxybenzoyl chloride 
• 2215-77-2 4-Phenoxybenzoic acid 
• 21218-94-0 methyl 4-phenoxybenzoate 
• 330792-69-3 2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile 
• 1055710-57-0 2-[amino(4-phenoxyphenyl)methylene]malononitrile 

Downstream Products

• 928309-79-9 C₂₄H₁₉BrN₄O 
• 1207957-96-7 C₂₅H₂₁BrN₄O 
• 928309-83-5 C₂₅H₂₁BrN₄O₂ 
• 928309-86-8 C₂₅H₂₁BrN₄O₂ 
• 1558038-40-6 C₂₇H₂₉N₅O₃ 
• 1558038-41-7 C₂₂H₂₃N₅O₂ 
• 1558037-08-3 C₃₀H₃₄N₆O₄ 
• 1558036-72-8 C₂₆H₂₅N₅O₃ 
• 1558038-55-3 C₂₈H₃₃N₅O₄ 
• 1558037-28-7 C₂₆H₂₇N₅O₃ 
• 1558038-54-2 C₂₈H₃₁N₅O₃ 
• 1612774-47-6 tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)-piperidine-1-carboxylate 
• 1612774-50-1 (R)-tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-51-2 (R)-tert-butyl 3-(5-amino-4-carbamoyl-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 

Relevant articles and documents

Regioselective Synthesis of Highly Functionalized Pyrazoles from N-Tosylhydrazones

A regioselective synthesis of highly functionalized pyrazoles from N-tosylhydrazones was developed. The reaction was general for a wide range of substrates and demonstrated excellent tolerance to a variety of substituents, and the method has been successfully applied to the formal synthesis of ibrutinib.

Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor

Therapeutic combinations of a proteasome inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a proteasome inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS

Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.

Methods of Using BTK Inhibitors to Treat Dermatoses

In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat dermatoses, such as psoriasis, atopic dermatitis, contact dermatitis, scleroderma, and cutaneous lupus erythematosus. In other embodiments, the methods of the invention further comprise the step of administering a therapeutically effective dose of an anti-inflammatory agent.

USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS

A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. A pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.

A according to lu tini and its key intermediate for the preparation of the new method (by machine translation)

The invention relates to a according to lu tini and its key intermediate for the preparation of the new method, the existing synthetic process avoids the more stringent reaction conditions, and the expensive starting material and reagent. The oxide by a one-pot reaction synthesis of key intermediate, simplified post-processing operation is relatively complex, and the cost is reduced. The obtained intermediate purity of 99% or more, the yield is higher, the operation is simple, and is suitable for industrial production. (by machine translation)

CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF

The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF

The present invention relates to a crystalline form of (S) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyri midine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

INHIBITOR OF BRUTON'S TYROSINE KINASE

Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.

THERAPEUTIC COMBINATIONS OF A CD19 INHIBITOR AND A BTK INHIBITOR

Therapeutic combinations of a CD 19 inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a CD 19 inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer, such as a hematological malignancy. A combination of a BTK inhibitor and a CD 19 inhibitor, such as a CD19-targeted antibody or a CD19-targeted chimeric antigen receptor expressing T cell or NK cell, and compositions and uses thereof are disclosed. Combinations of a BTK inhibitor and a CD 19 inhibitor with a programmed death- 1 (PD-1) or PD-1 ligand (PD-L1) inhibitor and compositions and uses thereof are also disclosed.